share_log

Abbott Laboratories | 8-K: Abbott Reports Third-Quarter 2024 Results and Raises Midpoint of Full-Year EPS Guidance Range

Abbott Laboratories | 8-K: Abbott Reports Third-Quarter 2024 Results and Raises Midpoint of Full-Year EPS Guidance Range

雅培 | 8-K：雅培公布2024年第三季度业绩并提高全年每股收益指导区间的中点
美股SEC公告 ·  2024/10/16 19:42

Moomoo AI 已提取核心信息

Abbott reported Q3 2024 sales of $10.6 billion, up 4.9% year-over-year, with organic sales growth of 8.2% excluding COVID-19 testing. Medical Devices led growth with 13.3% organic increase, driven by strong performance in Diabetes Care, Structural Heart, and Electrophysiology. The company posted GAAP EPS of $0.94 and adjusted EPS of $1.21.The company raised its full-year 2024 adjusted EPS guidance to $4.64-$4.70, reflecting continued momentum across its diversified portfolio. Abbott's board authorized a new $7 billion share repurchase program in October. Notable developments include a partnership with Medtronic for CGM integration and the U.S. launch of Lingo, Abbott's first over-the-counter continuous glucose monitoring system.Regional performance showed U.S. sales growing 10.1% to $4.2 billion, while international sales increased 1.7% to $6.4 billion. The company maintained its full-year 2024 organic sales growth guidance of 9.5-10.0%, excluding COVID-19 testing sales, which declined to $265 million in Q3 compared to $305 million last year.
Abbott reported Q3 2024 sales of $10.6 billion, up 4.9% year-over-year, with organic sales growth of 8.2% excluding COVID-19 testing. Medical Devices led growth with 13.3% organic increase, driven by strong performance in Diabetes Care, Structural Heart, and Electrophysiology. The company posted GAAP EPS of $0.94 and adjusted EPS of $1.21.The company raised its full-year 2024 adjusted EPS guidance to $4.64-$4.70, reflecting continued momentum across its diversified portfolio. Abbott's board authorized a new $7 billion share repurchase program in October. Notable developments include a partnership with Medtronic for CGM integration and the U.S. launch of Lingo, Abbott's first over-the-counter continuous glucose monitoring system.Regional performance showed U.S. sales growing 10.1% to $4.2 billion, while international sales increased 1.7% to $6.4 billion. The company maintained its full-year 2024 organic sales growth guidance of 9.5-10.0%, excluding COVID-19 testing sales, which declined to $265 million in Q3 compared to $305 million last year.
雅培报告2024年第三季度销售额为106亿，同比增长4.9%，不包括COVID-19检测的有机销售增长为8.2%。医疗设备以13.3%的有机增长引领增长，得益于糖尿病护理、结构性心脏疾病和心脏电生理领域的强劲表现。公司公布的公认会计原则每股收益为0.94美元，调整后的每股收益为1.21美元。公司将2024全年调整后的每股收益指导提升至4.64-4.70美元，反映出其多元化产品组合持续增长的势头。雅培董事会在10月授权了一项新的70亿美元股票回购计划。值得注意的发展包括与美敦力在CGM集成上的合作，以及雅培首个非处方连续血糖监测系统Lingo在美国的上市。区域业绩显示，美国销售增长10.1%，达到42亿，而国际销售增长1.7%，达到64亿。公司维持2024年全年有机销售增长指导为9.5-10.0%，不包括COVID-19检测销售，第三季度此项销售下降至26500万美元，去年为30500万美元。
雅培报告2024年第三季度销售额为106亿，同比增长4.9%，不包括COVID-19检测的有机销售增长为8.2%。医疗设备以13.3%的有机增长引领增长，得益于糖尿病护理、结构性心脏疾病和心脏电生理领域的强劲表现。公司公布的公认会计原则每股收益为0.94美元，调整后的每股收益为1.21美元。公司将2024全年调整后的每股收益指导提升至4.64-4.70美元，反映出其多元化产品组合持续增长的势头。雅培董事会在10月授权了一项新的70亿美元股票回购计划。值得注意的发展包括与美敦力在CGM集成上的合作，以及雅培首个非处方连续血糖监测系统Lingo在美国的上市。区域业绩显示，美国销售增长10.1%，达到42亿，而国际销售增长1.7%，达到64亿。公司维持2024年全年有机销售增长指导为9.5-10.0%，不包括COVID-19检测销售，第三季度此项销售下降至26500万美元，去年为30500万美元。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间